{"page_content": "Appendix\n70  |  ENVIRONMENTAL, SOCIAL & GOVERNANCE REPORT 2021\nIntroduction COVID-19 Response Healthy People Healthy Society Healthy Planet A Healthy Amgen\nSASB TOPIC ACCOUNTING METRICUNIT OF\nMEASURECODE REPORTING\nPercentage change in: (1) list price and (2) net price of \nproduct with largest increase compared to previous yearPercentage (%) HC-BP-240b  .3 Pertinent reporting can be found in the Our Approach to \nPricing, Access and Affordability and Amgen\u2019s Approach \nto Responsible Pricing sections of our website; the \nManagement, Discussion and Analysis and Risk Factors \nsections of the 10-K and 10-Qs; and the Approach to Pricing \nOur Products section of the 2022 Proxy Statement (within \nthe Compensation Discussion and Analysis subsection) .\nDrug SafetyList of products listed in the Food and Drug Administration\u2019s \n(FDA) MedWatch Safety Alerts for Human Medical \nProducts databasen/a HC-BP-250a .1 See FDA MedWatch database  .\nNumber of fatalities associated with products as \nreported in the FDA Adverse Event Reporting SystemNumber HC-BP-250a .2 See FDA Adverse Event Reporting System .\nNumber of recalls issued, total units recalled Number HC-BP-250a .3 See the 2021 Highlights in the \u201cA Healthy Amgen\u201d section \nof this Report; further, Amgen discloses material legal and \nregulatory issues in its annual 10-K and quarterly 10-Qs  .\nTotal amount of product accepted for take-back, reuse, \nor disposalMetric tons (t) HC-BP-250a .4 Data on product accepted through take-back can be found \nin the Product Sustainability section of our website (see \nthe Product Packaging and Lifecycle section); in addition \nwe provide information about the California Safe Needle \nCollection and Disposal Plan .APPENDIX", "metadata": {"source": "NASDAQ_AMGN_2021.pdf", "page": 69, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}